EichorEICHOR
Condition: Stage Iv Lung Non Small Cell Cancer Ajcc V7 Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Stage Iv Lung Non Small Cell Cancer Ajcc V7

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used W
Phase 1/Phase 2 · 46 location(s) · Merck Sharp & Dohme LLC · NCT04165070ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06388031Electro-Acupuncture in Lung cancER : EALER Study
NA · 3 location(s) · Guangzhou University of Traditional Chinese Medicine · NCT07337096A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06498986This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · 372 location(s) · Pfizer · NCT06758401A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Phase 2 · 5 location(s) · Abbisko Therapeutics Co, Ltd · NCT06668103Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
Phase N/A · 1 location(s) · Gene Solutions · NCT06167460Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Phase 3 · 1 location(s) · Peking Union Medical College Hospital · NCT06674343A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · 304 location(s) · AstraZeneca · NCT06868277A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · University of Washington · NCT05242965A Phase Ib Study of GC101 in NSCLC
Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT06473961A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Phase 3 · 1 location(s) · Beijing Pearl Biotechnology Limited Liability Company · NCT05989542A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · 402 location(s) · Pfizer · NCT07144280Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Phase 2 · 1 location(s) · Dizal Pharmaceuticals · NCT06276283A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Trea
Phase 1/Phase 2 · 5 location(s) · Henan Genuine Biotech Co., Ltd. · NCT07231068A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Phase 1/Phase 2 · 21 location(s) · Allist Pharmaceuticals, Inc. · NCT05276726A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06863233LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
NA · 3 location(s) · Institut Curie · NCT04790682Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Phase 2 · 18 location(s) · Memorial Sloan Kettering Cancer Center · NCT04410796A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07056556Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell
Phase 1/Phase 2 · 9 location(s) · National Cancer Institute (NCI) · NCT07012031Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT03199651A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR
Phase 2 · 80 location(s) · Taiho Oncology, Inc. · NCT05967689Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Phase 3 · 1 location(s) · CSPC Megalith Biopharmaceutical Co.,Ltd. · NCT06927986Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3 · 2 location(s) · TYK Medicines, Inc · NCT05382728A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 5 location(s) · Avistone Biotechnology Co., Ltd. · NCT07538804First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H
Phase 1/Phase 2 · 24 location(s) · Pierre Fabre Medicament · NCT06043817A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Sm
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06589778A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07489716
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.